The components of drug-linker conjugates for antibody drug conjugates (ADCs) are a cytotoxic drug that is active and a suitable linker. These conjugates can be used to create ADCs, which are highly selective and cytotoxic agents that are targeted for cancer cells after being joined to a monoclonal antibody.
The drug units in drug-linker conjugates are tubulin inhibitors and DNA damaging agents that have antitumor activity (i.e., ADC cytotoxins or payloads). Auristatins and Maytansinoids are the most widely used tubulin inhibitors, while Duocarmycins, Pyrrolobenzodiazepines, Camptothecines, and Daunorubicins/Doxorubicines are the most frequently used DNA damaging agents in ADCs. Additionally, a variety of conventional cytotoxic agents can be used in ADCs.
Cleavable and noncleavable ADC linkers are the two categories into which the majority of those currently undergoing clinical evaluation fall. Noncleavable linkers necessitate proteolytic degradation of the antibody component of the ADC in order to release the cytotoxic molecule, whereas cleavable linkers depend on cellular processes to release the toxin.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V53342 | TAM558 | 1802499-21-3 | TAM558 is the payload molecule used in the synthesis/preparation of OMTX705. |
|
V51775 | TLR7/8 agonist 4 hydroxy-PEG10-acid | 2388520-17-8 | drug-linker conjugate for ADC |
|
V51776 | TLR7/8 agonist 4 hydroxy-PEG10-acid HCl | 2388520-36-1 | drug-linker conjugate for ADC |
|
V54794 | TLR7/8 agonist 4 hydroxy-PEG6-acid | 2388520-23-6 | TLR7/8 agonist 4 hydroxy-PEG6-acid is an ADC drug-linker conjugates (Drug-Linker Conjugates for ADC). |
|
V76409 | TLR7/8 agonist 4 hydroxy-PEG6-acid hydrochloride | TLR7/8 agonist 4 hydroxy-PEG6-acid HCl is an ADC drug-linker conjugates (Drug-Linker Conjugates for ADC). | |
|
V77711 | Tyrosine-PEG4-aminooxy-MMAF | Tyrosine-PEG4-aminooxy-MMAF is a linker-payload conjugate that may be utilized to prepare ARX788. | |
|
V53013 | Val-Ala-PAB-MMAE | 1912408-92-4 | Val-Ala-PAB-MMAE is a drug-linker conjugates for ADC (Drug-Linker Conjugates for ADC), consisting of ADC linker (Val-Ala-PAB) and MMAE, which is an effective microtubule ( tubulin) inhibitor. |
|
V53292 | Val-Ala-PABC-Exatecan | 2845164-91-0 | Val-Ala-PABC-Exatecan is a drug-linker conjugate (Drug-Linker Conjugates for ADC), consisting of cleavable Tesirine linker and Exatecan (topoisomerase I inhibitor). |
|
V29789 | Val-Cit-PAB-MMAE | 644981-35-1 | Val-Cit-PAB-MMAE is a drug-linker conjugate used for preparing ADC (antibody-drug-conjugate) with monomethyl auristatin E (MMAE), a highly potent anti-mitotic agent as a cytotoxicin/warhead, linked via the peptide Val-Cit-PAB. |
|
V54774 | Vat-Cit-PAB-Monomethyl Dolastatin 10 | 1415329-13-3 | Vat-Cit-PAB-Monomethyl Dolastatin 10 is a part of the antibody conjugation active molecule, which is made up of Monomethyl Dolastatin 10 (a potent tubulin inhibitor) and the ADC linker Vat-Cit-PAB. |
|
V4642 | VcMMAE (mc-vc-PAB-MMAE) | 646502-53-6 | VcMMAE(mc-vc-PAB-MMAE),a derivative of MMAE (monomethyl auristatin E) with a valine-citrulline (Vc) linker, is adrug-linker conjugate for ADC(antibody-drug-conjugate) with potent antitumor activity by utilizing the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). |
|
V5114 | Vipivotide tetraxetan (PSMA-617) | 1702967-37-0 | Vipivotide tetraxetan (also known as PSMA-617) is a novel and highly potent prostate-specific membrane antigen(PSMA)inhibitor with anticancer activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
